Search clinical trials for: Osimertinib Mesylate Tablets

Total 8338 results

Novartis Pharmaceuticals

Completed

Phase ll Study of Imatinib Mesylate for the Neoadjuvant Treatment of Patients With Gastrointestinal Stromal Tumors (GIST) (CONVERT)

Gastrointestinal Stromal Tumors

Brazil
Novartis

Completed

STI571 in Treating Patients With Chronic Myelogenous Leukemia in Blast Crisis

Leukemia

United States
Poitiers University Hospital
Novartis

Completed

Safety and Efficacy of Imatinib in Chronic Myelogenous Patients in Relapse After Stem Cell Transplantation

Chronic Myeloid Leukemia

France
OHSU Knight Cancer Institute
National Cancer Institute (NCI)

Terminated

Imatinib Mesylate in Treating Patients With Myelofibrosis

Chronic Myeloproliferative Disorders

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor

Sarcoma

United States
Jiangsu HengRui Medicine Co., Ltd.

Recruiting

A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibroids

Uterine Fibroids With Menorrhagia

China
Galapagos NV

Completed

Efficacy and Safety of GLPG0634 in Subjects With Active Crohn's Disease

Crohn's Disease

United Kingdom, Belgium, France, Hungary, Russian Federation, Czech Republic, Germany, Poland, Romania
National Cancer Institute (NCI)

Withdrawn

Testing the Safety of CB-5339 in Patients With Cancer

Locally Advanced Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | Aggressive Non-Hodgkin Lymphoma | Indolent Non-Hodgkin Lymphoma

United States
Li Zhang, MD

Not yet recruiting

Phase III Study Comparing Osimertinib Monotherapy to Combination Therapy With Osimertinib,Carboplatin and Pemetrexed for Untreated Patients With Advanced Non-squamous Non-Small Cell Lung Cancer With Concurrent EGFR and TP53 Mutations (TOP)

Non-small Cell Carcinoma | EGFR Gene Mutation

China
Shanghai Ninth People's Hospital Affiliated to...

Completed

A Study of Apatinib and Tegafur Gimeracil Oteracil in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

Head and Neck Squamous Cell Carcinoma

China
Ain Shams University
Cairo University

Recruiting

Pharmacokinetics, Safety, Efficacy and Acceptability of Daclatasvir Plus Sofosbuvir in HCV-infected Children

HCV

Egypt
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Relative Bioavailability Study of SHR3680 (SHR-3680)

Healthy Male Subjects

China
GlaxoSmithKline

Completed

GSK189075, GW869682 Or Placebo In Type 2 Diabetic Patients

Diabetes Mellitus, Type 2 | Non-Insulin-Dependent Diabetes Mellitus

Germany, United States
Sunshine Lake Pharma Co., Ltd.

Completed

The Safety, Tolerability, and Pharmacokinetics Study of HEC113995 PA•H2O Tablets in Healthy Subjects

Major Depressive Disorder

China
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

A Study of SPH3127 in the Treatment of Mild to Moderate Ulcerative Colitis

Mild to Moderate Ulcerative Colitis

China
Boehringer Ingelheim
Eli Lilly and Company

Completed

Relative Bioavailability of 2 Fixed Dose Combinations of Empagliflozin/Metformin Compared With Single Tablets

Healthy

United States
Sunshine Lake Pharma Co., Ltd.

Recruiting

A Clinical Trial to Evaluate Clifutinib in Patients With Relapsed or Refractory Acute Myeloid Leukemia(AML)

Acute Myeloid Leukemia

China
Swiss Group for Clinical Cancer Research

Terminated

Eribulin as 1st Line Treatment in Elderly Patients With Advanced Breast Cancer

Adenocarcinoma | Breast Cancer

Switzerland
Novartis

Terminated

Open-label Trial of Imatinib Mesylate in Patients With Unresectable Recurrent Glioblastoma Multiforme Expressing PDGFR (Platelet Derived Growth Factor Receptors)

Glioblastoma

Brazil
European Organisation for Research and Treatment...

Completed

Imatinib Mesylate in Treating Patients With Gliomas

Brain and Central Nervous System Tumors

France, Switzerland, Italy, Belgium, Austria, United Kingdom, Netherlands
Tianjin Chasesun Pharmaceutical Co., LTD
Southwest Hospital, China

Completed

Phase I Study of Kukoamine B Mesilate in Healthy Volunteers

Healthy

China
Asan Medical Center

Completed

Adjuvant Imatinib in High-risk Gastrointestinal Stromal Tumor (GIST) With C-kit Mutation

Sarcoma | Gastrointestinal Stromal Tumors

Korea, Republic of
AIDS Malignancy Consortium
National Cancer Institute (NCI); The Emmes Company, LLC

Completed

Imatinib Mesylate in Treating Patients With HIV-Related Kaposi's Sarcoma

Sarcoma

United States
Novartis Pharmaceuticals

Completed

Five Year Adjuvant Imatinib Mesylate (Gleevec®) in Gastrointestinal Stromal Tumor (GIST)

Gastrointestinal Stromal Tumor (GIST)

United States
Novartis Pharmaceuticals

Completed

Study Comparing Standard Dose and High-dose Imatinib Mesylate in Patients With Chronic Phase Philadelphia Chromosome Positive (Ph+) Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

Canada
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Refractory or Relapsed Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer, or Ovarian Low Malignant Potential Tumor

Ovarian Cancer | Fallopian Tube Cancer | Primary Peritoneal Cavity Cancer

United States
Barbara Ann Karmanos Cancer Institute
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Novartis Pharmaceuticals

Terminated

Imatinib Mesylate Treatment of Patients With Malignant Peripheral Nerve Sheath Tumors

Malignant Peripheral Nerve Sheath Tumors

Germany
Daniels, Craig E., M.D.
Novartis

Completed

Gleevec Idiopathic Pulmonary Fibrosis (IPF) Study

Idiopathic Pulmonary Fibrosis | Pulmonary Fibrosis | Lung Disease
Hansoh BioMedical R&D Company

Recruiting

A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis

Psoriasis

China
The Netherlands Cancer Institute

Completed

Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir

Cancer

Netherlands
GlaxoSmithKline

Completed

Valaciclovir Hydrochloride Phase III for Hematopoietic Stem Cell Transplantation Patients

Herpes Simplex

Japan
Hanmi Pharmaceutical Company Limited

Completed

Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)

Advanced Solid Malignancies

Korea, Republic of
AstraZeneca
Parexel

Completed

A Study to Assess the Bioavailability of Different Formulations of AZD5718 and the Food Effect on the Selected Formulation of AZD5718 in Healthy Volunteers

Coronary Artery Disease

United Kingdom
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Recruiting

A Clinical Trial of TQ-A3334 Tablet After Multiple Administration in Adult Subjects

Hepatitis B

China
Nanjing Sanhome Pharmaceutical, Co., Ltd.

Recruiting

SH-1028 Tablets Versus Placebo as Adjuvant Therapy in Resected Stage II-IIIB NSCLC With Sensitizing EGFR Mutations

Non-small Cell Lung Cancer

China
Changchun Huayang High-tech Co., Ltd
Beijing Bionovo Medicine Development Co., Ltd.

Unknown

Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease

Alzheimer's Disease

China
Peking Union Medical College Hospital

Completed

Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer (ACABC)

Cholangiocarcinoma | Hepatobiliary Neoplasm | Biliary Tract Cancer | Biomarker

China
Peking University

Recruiting

Apatinib With Oxaliplatin and S-1 Treatment for Advanced Hepatoid Adenocarcinoma Of The Stomach

Gastric Cancer

China
Point Therapeutics

Terminated

Trial of Talabostat and Gemcitabine in Patients With Stage IV Adenocarcinoma of the Pancreas

Adenocarcinoma | Neoplasm Metastasis | Pancreatic Cancer

United States
Memorial Sloan Kettering Cancer Center
AstraZeneca; Genentech, Inc.

Completed

Osimertinib and Bevacizumab as Treatment for EGFR-mutant Lung Cancers

Non-small Cell Lung Cancer | EGFR-mutant Lung Cancers

United States
Sunshine Lake Pharma Co., Ltd.

Suspended

Evaluation HEC121120 Tolerance in Healthy Subjects and Patients With Chronic Hepatitis B, Pharmacokinetics Characteristics and Antiviral Activity of Ⅰ Phase of Study

Hepatitis B, Chronic

China
Bennett, Robert, M.D.
Merck Sharp & Dohme LLC

Completed

Efficacy and Safety of an Oral Growth Hormone Drug in the Treatment of Fibromyalgia

Fibromyalgia

United States
Tan Tock Seng Hospital

Unknown

A Pilot Study of Eribulin in Breast Cancer (BC) Patients With Brain Metastases Previously Treated With Anthracyclines and Taxanes

Breast Cancer

Singapore, Taiwan
University of Texas Southwestern Medical Center

Recruiting

Mitoquinone/Mitoquinol Mesylate as Oral and Safe Postexposure Prophylaxis for Covid-19

COVID-19 | SARS-CoV Infection

United States
Eisai Inc.

Completed

Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer

Breast Cancer

United States
Eisai Inc.

Completed

Study to Evaluate the Efficacy and Safety of Eribulin Mesylate Administered Biweekly (Q2W) for Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Metastatic Breast Cancer

Breast Cancer

United States
Antipodean Pharmaceuticals, Inc.

Terminated

A Study to Compare MitoQ and Placebo to Treat Non-alcoholic Fatty Liver Disease (NAFLD) (MARVEL)

Non-alcoholic Fatty Liver Disease

United Kingdom
Antipodean Pharmaceuticals, Inc.

Completed

Trial of MitoQ for Raised Liver Enzymes Due to Hepatitis C

Chronic Hepatitis C

New Zealand
University of Alabama at Birmingham

Terminated

TXA and Corona Virus 2019 (COVID19) in Outpatients (TCOutpatient)

COVID-19

United States

3

Subscribe